Avalyn Pharma
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 year.
- Recent price momentum is -23.5% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 5.2% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Performance
Key statistics
Price & volume
- Prev close
- 28.70
- Open
- 28.06
- Day range
- 27.85 - 29.38
- Avg price
- 28.50
- Volume
- 214.30K
- Turnover
- 6.11M
- Turnover ratei
- 0.71%
- Volume ratioi
- 0.49
- Amplitudei
- 5.35%
- 52-week rangei
- 22.24 - 40.17
Valuation
- P/Ei
- -13.94
- P/E (TTM)i
- -11.53
- P/Bi
- 3.42
- EPSi
- -2.04
- Book value / shi
- 8.32
- Net profit
- -90.73M
- Net assets
- 370.24M
Share structure
- Market cap
- 1.26B
- Float capi
- 861.00M
- Shares out
- 44.52M
- Float sharesi
- 30.32M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2026-04-30
29.3% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-2.32M net over the window
Short interest
- Shares short
- 2.30M
- % of floati
- 5.19%
- Days to coveri
- 5.30
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Avalyn Pharma (AVLN)?
Avalyn Pharma last traded at 28.40. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Avalyn Pharma's market cap?
About 1.26B.
What is the P/E ratio of Avalyn Pharma?
The trailing twelve-month P/E is -11.53. The Valuation tab shows it against the stock's own five-year range.
Does Avalyn Pharma pay a dividend?
Avalyn Pharma does not currently pay a regular dividend.
Is Avalyn Pharma a buy according to analysts?
The consensus of 1 analysts is a Buy rating, with an average 12-month price target of 60.00, which implies 111.3% upside from the current price. This is not investment advice.
What is Avalyn Pharma's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Avalyn Pharma a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Avalyn Pharma discussion 0 comments